HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA


SEOUL, South Korea, ‘HemoHim,’ an immune-boosting health supplement from Kolmar BNH (KRX: 200130), has earned international recognition for its quality from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), enhancing its credibility in the global marketplace.

Kolmar BNH announced that its Sejong plant obtained a No Action Indicated (NAI) classification following an inspection by the U.S. FDA in September. This classification, which confirms that the facility fully complies with U.S. Current Good Manufacturing Practice (cGMP) standards for quality control, has further intensified Kolmar BNH’s competitiveness as a leading global Original Development Manufacturer (ODM) in the health supplement industry.

Source: BERNAMA News Agency

  • malaysiang

    Related Posts

    Part 1: Dreams Grounded: Malaysian Aviation Trainees Left In Financial Ruin By Aviation Company

    (This is the first of a three-part series on how aspiring aviators’ dream of taking to the skies came crashing down when a local company, facilitating their training programme in the Czech Republic, failed to honour its obligations. Part I delves into…

    New Committee Formed To Rationalise Federal Statutory Bodies And GLCs- Anwar

    KUALA LUMPUR, The government has established a Special Committee for the Rationalisation of Federal Statutory Bodies, including Companies Limited by Guarantee, to address the duplication of functions and misuse of national funds in statutory bodies an…